by John Conrad | Oct 28, 2024 | Member News, NewsBrief
Chicago-headquartered Iterum Therapeutics (Nasdaq: ITRM) has received U.S. Food and Drug Administration (FDA) approval for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited...
by John Conrad | Jul 19, 2024 | NewsBrief
In a strategic move to expand its specialty biopharmaceuticals portfolio, Meitheal Pharmaceuticals has acquired the North American rights to CONTEPO™ (fosfomycin for injection) from Nabriva Therapeutics. The announcement, made on July 18, 2024, marks a significant...